Keros Therapeutics Inc（KROS）财务数据KROSKeros Therapeutics Inc

Evaluating the bottom line, Keros Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15480.65%, while the net margin is -14282.83%. These profitability ratios, combined with a Return on Equity (ROE) of -17.16%, provide a clear picture of how effectively KROS converts its operational activities into shareholder value.

In the context of the broader market, KROS competes directly with industry leaders such as PLX and SLGL. With a market capitalization of $220.08M, it holds a significant position in the sector. When comparing efficiency, KROS's gross margin of 100.00% stands against PLX's 60.99% and SLGL's 100.00%. Such benchmarking helps identify whether Keros Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Keros Therapeutics has shown fluctuating revenue, with a significant drop to $367,000 in Q1 2026 and $0 in Q2 2026, indicating potential operational challenges. The gross margin remains high at 100%, but net income has been consistently negative, highlighting ongoing financial struggles.